Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 899

Sectra Digital Pathology Module Receives FDA Clearance

International medical imaging IT and cybersecurity company Sectra has received a 510(k) clearance by the US Food & Drug Administration (FDA). The clearance applies for Sectra Digital Pathology Module, the key component of Sectra’s pathology solution, when used together with Leica Biosystems’ scanner AT2 DX.

This enables US healthcare providers to use Sectra’s digital pathology solution for primary diagnostics. The solution makes it possible to move towards fully integrated diagnostics, which is especially important in complex cancer cases.

Mikael Anden, President, Sectra Inc. notes, “I’m excited that with the FDA approval, we are now able to offer US healthcare providers a digital pathology offering with a proven track-record of use for full-scale primary diagnostics and large volumes.” Anden added, “Our solution makes it possible for pathologists across the country to continue their important work from home without the need for a microscope. We look forward to providing uninterrupted pathology reading in these challenging times. This approval is an exciting and important step forward for pathology and cancer care in the US.”

Sectra’s digital pathology solution is already used in the US for research and tumor boards and can now also be used in primary diagnostics. With digital images of tissue samples instead of physical glass slides, pathologists gain instant access to current and historical images and related data as well as to digital tools for reviewing the images. Digital access also facilitates efficient second opinions, remote reading, specialist consultations and makes integrated diagnostics possible.

The digital pathology solution is a component of Sectra’s enterprise imaging offering, of which all components are built on the same technical platform. This allows healthcare providers to use a single solution for their medical imaging needs across all specialties, enabling integrated diagnostics. A deeper cooperation and ability to access other departmental images and information contributes to improved efficiency and patient care. This is especially important for complex cases where both radiology and pathology play key roles. Instant access to digital pathology images, side by side with radiology or other images, enables more efficient discussions and the ability to give detailed descriptions of findings.

“Pathology is the next huge digitization of healthcare. The use of glass slides limits growth in today’s increasingly digital environment, especially in consolidated health care systems where potential synergies cannot be reached unless pathology is digitized. Our solution opens up new opportunities in the US where we can point to our successes in Europe in large production centers,” says Dr. Torbjörn Kronander, President and CEO of Sectra.

COVID Care’s COVID-19 IgG and IgM Rapid Test Now Authorized Pursuant to FDA EUA Guidance

The FDA Approved Rapid COVID-19 Test Kits for Medical Professionals, First Responders, and Law Enforcement detects IgG and IgM antibodies to SARS-CoV-2 in human blood, is now available reports Molecule Holdings.

The Covid Care Rapid Test has a 91% Clinical Sensitivity rating, and a 99% Clinical Specifity rating.

Medical professionals are adamant just how critical it is to have access to rapid, point of care testing, that is both simple and affordable. PCR testing technology takes multiple days to yield results and is not a scalable or an affordable solution to answering the extent of community and worldwide COVID-19 testing needs.

The COVID Care testing kits are FDA Approved under the Emergency Use Act and come from Pinnacle BioLabs, an FDA registered laboratory in Tennessee. They are manufactured in an ISO-13485 Certified Facility. The kits have undergone significant preliminary clinical testing and the results are in…

COVID Care tests return results with Diagnostic Specificity higher than 90%!

Testing with the COVID Care test is easy and resembles the tests diabetics use to test their blood sugar.

Simply “prick” a finger with the included lance, drip 2 drops of blood into the included testing cassette, drip 2 drops of testing solution into the cassette, and wait approximately 5 minutes for results. Interpreting results is a very straightforward process.

Datos Health COVID-19 Solution Employed at Rochester Regional Health

Datos Health is a provider of an automated remote care platform, together with Rochester-based consulting firm Strategic Interests, LLC. Today it was announced the successful deployment of the Datos COVID-19 solution at Rochester Regional Health.

The partnership is enabling Rochester Regional Health to more efficiently and safely monitor patients and healthcare workers exposed to or suffering from coronavirus, outside of the hospital setting.

“Given the current trajectory of the pandemic in major metropolitan areas, as COVID-19 continues to spread, hospitals may experience a surge in visitors, resulting in many health systems like ours quickly becoming overwhelmed and adding further burden on an already overstretched medical system,” said Bridgette Wiefling, MD, Senior VP for the Primary Care and Ambulatory Specialty Institute at Rochester Regional Health. “At Rochester Regional, we strive to provide optimal care to the patients in our community, while investing in our team members who put their lives on the line every day. This tool enables us to deliver great quality care and bring comfort to those who are on the frontline in fighting this disease.”

The Datos Health solution is specifically designed to support hospitals across the world to alleviate the strain on healthcare systems by helping to keep suspected coronavirus patients and those who are infected but do not require hospitalization, at home while still providing them with optimal care.

Rochester Regional is using the Datos Remote Care platform to monitor three groups of people:

  1. Staff at low risk of exposure, yet required to report their temperature twice daily for 14 days
  2. Staff displaying symptoms and tested positive for COVID-19
  3. Patients required to self-quarantine for 14 days due to displaying symptoms consistent with COVID-19 but having not met the testing criteria.

“Our remote care platform solution is helping healthcare systems like Rochester Regional to vastly improve communication between patients and care workers, providing reassurance during the challenging isolation period that they are still being cared for and will receive any further interventions if needed,” said Uri Bettesh, CEO of Datos Health. “For hospitals, this also provides the ability to safeguard employees, monitoring them for compliance and enabling them to return quickly to work once out of the isolation period.”

“This project is helping our client Rochester Regional Health to rapidly deploy critical and unique capabilities that can keep our community safe during these uncertain times, and we are honored to have played a supporting role in bringing together the dedicated clinicians and administrators at Rochester Regional with Datos’ dynamic team,” said Al Kinel, President, Strategic Interests. “It is remarkable that, in just a few short days, they were able to implement an innovative and efficient solution to preserve the dedicated medical staff and ensure the well-being of non-hospitalized patients.”

FDA Continues to Accelerate Development of Novel Therapies for COVID-19

As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments.

The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.

“The FDA is announcing a new, comprehensive public-private approach to bring coronavirus treatments to market as fast as possible,” said HHS Secretary Alex Azar. “As part of this new program, the FDA is cutting red tape, redeploying staff and working day and night to review requests from companies, scientists and doctors who are working toward therapies. We are grateful to the men and women of the FDA who have been working in concert with industry and other parts of HHS to support potential coronavirus treatments for weeks now. Each day, President Trump’s all-of-America approach is making progress and providing new hope in our fight against the coronavirus.”

There are a large number of companies and researchers developing and evaluating COVID-19 related therapies. Given the urgent nature of the pandemic, under the FDA’s accelerator program, staff from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research are providing regulatory advice, guidance and technical assistance as quickly as possible. As part of this work, the FDA is triaging requests from developers and scientists seeking to develop new drug and biologic therapies, getting the relevant FDA staff in touch with them and providing rapid, interactive input to get studies underway quickly. For example, the FDA has reviewed study protocols within 24 hours in many cases and has reviewed single-patient expanded access requests generally within three hours. The FDA is also collaborating with federal partners, developers and researchers to create protocols that can be used across institutions and programs to streamline efforts.

“Quickly after the emergence of this virus, we began working directly with federal health partners, academia and industry to advance medical countermeasures against COVID-19. Our staff continues to work across all sectors to expedite the development of numerous, innovative potential prevention and treatment approaches. We are also looking at pragmatic and expedited ways to make these products available to patients, while still ensuring the FDA’s standards are met,” said FDA Commissioner Stephen M. Hahn. “Accelerating the investigation of products that could potentially benefit people affected by the COVID-19 pandemic is one of the FDA’s highest priorities. We want to help patients by expediting promising treatments and are committed to maximizing our regulatory flexibility and proactively bringing the best innovators together to ensure we are getting the right treatments to the right patients at the right time.”

To support these goals, the FDA has, among other things, redeployed medical and regulatory staff to serve on review teams dedicated to COVID-19 therapies, streamlined processes and operations for developers and scientists to send inquiries and requests and provided resources to health care providers and researchers to help them submit emergency requests to use investigational products.

There are a variety of therapeutic areas being evaluated, including antiviral drugs like remdesivir that might treat the specific virus, as well as host targets, such as interleukin-6 (IL-6) receptor inhibitors that may be helpful in reducing lung inflammation and improving lung function in COVID-19 patients. There’s also interest in examining whether therapies such as convalescent plasma and hyperimmune globulin, antibody-rich blood products that are taken from blood donated by people who have recovered from the virus, could shorten the length or lessen the severity of the illness. Work is also ongoing to evaluate whether existing therapies such as chloroquine and hydroxychloroquine (with or without other medications) help treat patients with COVID-19.

The FDA also recognizes the potential for many different real-world data sources to complement traditional clinical studies and speed the process of evaluating the impact of potential COVID-19 therapies. To that end, the agency is advancing relationships with partners in the public and private sectors to rapidly collect and analyze information in areas such as illness patterns and treatment outcomes.

The FDA’s efforts to facilitate the development of COVID-19 therapies are focused on expediting the development of data on these medical countermeasures that can meet the agency’s world-respected gold standard for full FDA approval, which relies on data from adequate and well-controlled trials to most efficiently determine if an experimental treatment can safely and effectively benefit patients.

The FDA will continue to enhance and expand its work across the federal government and innovators in academia and industry to accelerate COVID-19 treatments and other medical countermeasures. The agency will outline additional information in the near future to provide a greater understanding of the full breadth of work in this area, to the extent permitted by confidentiality laws.

Additional Resources:

Ventec Life Systems and GM Partner to Mass Produce Critical Care Ventilators in Response to COVID-19 Pandemic

On March 27, 2020, Ventec Life Systems announced that General Motors will build VOCSN critical care ventilators at GM’s Kokomo, Indiana manufacturing facility with FDA-cleared ventilators scheduled to ship as soon as next month. This effort is in addition to Ventec taking aggressive steps to ramp up production at their manufacturing facility in Bothell, Washington.

Across all manufacturers, there is a global backorder of critical care ventilators capable of supporting patients fighting COVID-19. The companies are adding thousands of units of new capacity with a significantly expanded supply chain capable of supporting high volume production. GM is donating its resources at cost.

GM will also begin manufacturing FDA-cleared Level 1 surgical masks at its Warren, Michigan manufacturing facility. Production will begin next week and within two weeks ramp up to 50,000 masks per day, with the potential to increase to 100,000 per day.

Critical Care Ventilators

“This unique partnership combines Ventec’s respiratory care expertise with GM’s manufacturing might to produce sophisticated and high-quality critical care ventilators,” said Chris Kiple, CEO of Ventec Life Systems. “This pandemic is unprecedented and so is this response, with incredible support from GM and their suppliers. Healthcare professionals on the front lines deserve the best tools to treat patients and precision critical care ventilators like VOCSN are what is necessary to save lives.”

Ventec and GM are working around the clock to meet the urgent need for more ventilators.  Efforts to set up tooling and manufacturing capacity at the GM Kokomo facility are already underway to produce Ventec’s critical care ventilator, VOCSN. Depending on the needs of the federal government, Ventec and GM are poised to deliver the first ventilators next month and ramp up to a manufacturing capacity of more than 10,000 critical care ventilators per month with the infrastructure and capability to scale further.

“We are proud to stand with other American companies and our skilled employees to meet the needs of this global pandemic,” said Mary Barra, GM chairman and CEO. “This partnership has rallied the GM enterprise and our global supply base to support Ventec, and the teams are working together with incredible passion and commitment. I am proud of this partnership as we work together to address urgent and life-saving needs.”

GM will deploy an estimated 1,000 American workers to scale production of critical care ventilators immediately. Working with the UAW, GM has brought back employees from GM’s Kokomo and Marion facilities.

Since Friday, March 20, Ventec and GM teams across manufacturing, engineering, purchasing, legal and others have been tirelessly and seamlessly working together to create and implement a plan for immediate, scaled production of critical care ventilators. The Ventec and GM global supply base developed sourcing plans for the more than 700 individual parts that are needed to build up to 200,000 VOCSN.

”GM is in the position to help build more ventilators because of the remarkable performance of GM and Ventec’s global supply base,” added Barra. “Our joint teams have moved mountains to find real solutions to save lives and fight the pandemic.”

The Ventec Life Systems team has a history of patient-centric design which includes more than 18 care-changing respiratory devices and more than 40 patents. Ventec’s leading product, VOCSN, is the first and only Multi-Function Ventilator and was FDA cleared in 2017. VOCSN seamlessly integrates five separate devices including a critical care ventilator, oxygen concentrator, cough assist, suction and nebulizer into a single portable device.  VOCSN provides invasive and non-invasive ventilation across a comprehensive set of modes and settings throughout the care continuum from the hospital to the home.

GM’s Kokomo facility supports the production of precision electrical components and is approximately 2.6 million square feet, located on more than 270 acres.

This partnership combines global expertise in manufacturing quality and a joint commitment to safety to give medical professionals and patients access to life-saving technology as rapidly as possible.

Level 1 Surgical Masks

In a separate effort, GM is expanding its support of medical equipment production by temporarily converting its Warren, Michigan plant to build Level 1 surgical masks. Production will begin next week and within two weeks ramp up to 50,000 masks per day, with the potential to increase to 100,000 per day. Daily mask production will be influenced by the availability of materials to build the masks.

The necessary machinery will be delivered to the Warren plant Friday morning and production of masks will begin next week.

This employee-led initiative was created, planned and approved in about 48 hours and involves GM’s traditional supply base as well as new partnerships specific to the medical device industry. GM will be collaborating with governments and local suppliers to distribute the masks.

Jupiter Medical Center Establishes Command Center to Bolster COVID-19 Preparedness

Since January, Jupiter Medical Center’s medical staff leadership, infection prevention experts and executive team have been developing plans to screen, isolate and treat COVID-19 patients, including conducting drills and training for hospital team members and ensuring the careful stewardship of equipment and supplies.

Jupiter Medical Center was one of the first hospitals to implement CDC guidelines for the screening, diagnosis, and treatment of COVID-19 and since has also been working closely with the Florida Department of Health to strictly adhere to state and federal guidelines.

To streamline and centralize hospital operations in order to address an expected increase in patient volume of COVID-19 patients, Jupiter Medical Center has established an Incident Command Center. Similar to the actions the regional medical center would take during a hurricane, the command center offers a dedicated structure to streamline communication and provide administrative oversight to manage patient treatment, clinical staffing, and the allocation of rooms, equipment and supplies.

“Consistent with leading national and regional hospitals across the country, we implemented a series of comprehensive measures early to improve our readiness,” said Dr. Amit Rastogi, president and chief executive officer. “In addition to strictly adhering to CDC guidelines, we initiated additional preventive measures and began multidisciplinary training to prepare our team members to recognize and screen potential cases, implement isolation protocols, and properly use personal protective equipment (PPE) while treating patients,” Dr. Rastogi continued.

The regional medical center also confirmed that it is starting to see patients who have tested positive for COVID-19. As required by federal privacy laws, Jupiter Medical Center is prevented from releasing any personal details about patients undergoing treatment.

Most recently, the medical center adopted The American College of Surgeons’ recommendations and began rescheduling non-urgent, elective surgeries to increase capacity and minimize the potential of COVID-19 exposure among patients, team members, and frontline providers.

“We will continue to perform nonelective, urgent and emergency surgeries,” Dr. Rastogi said. “However, by reducing the number of elective procedures, we are able to conserve our supply of personal protective equipment, beds, and ventilators for use in patients with critical illnesses, and ensure that more of our clinical team members are available to care for patients who are most in need when the time comes.”

Jupiter Medical Center is not a designated COVID-19 testing site, in accordance with directives from the Florida Department of Health. Public health authorities have advised that hospitals should not be used for non-critical conditions or non-emergencies, including coronavirus testing. Individuals experiencing symptoms – fever, cough or difficulty breathing – are urged to call their physician or contact one of several state-designated testing sites that are equipped to take swabs for testing and send them to the appropriate lab.

The medical center continues to engage national and regional suppliers to procure additional resources and supplies, such as test kits, N95 respirator masks, and ventilators, to identify and treat those who may require hospitalization. In addition to implementing the necessary personal protective equipment (PPE) to protect frontline caregivers, Jupiter Medical Center is leveraging the use of Tru-D SmartUVC ultra-violet disinfection robots that deconstruct the DNA of deadly pathogens and eliminate common health care-associated infection culprits.

Jupiter Medical Center has implemented a ‘no visitation’ policy with the exception of Labor & Delivery and Pediatric patients, who will be permitted one visitor. While the hospital recognizes this policy is highly inconvenient for patients and their loved ones, it is becoming necessary to reduce the likelihood of exposure.

The medical center has temporarily suspended health and wellness classes, professional CME and community events. Volunteer services and the hospital’s Motor Aid patient transport system also have been suspended.

If you or a loved one are exhibiting symptoms of COVID-19, members of the public are advised to call their primary care provider (PCP) for a screening. Or you may call the Florida Department of Health’s COVID-19 hotline which is available 24 hours a day and 7 days a week at 1 (866) 779-6121.

Northwell Health Converts BiPAP Machines Into Ventilators for Hospitalized COVID-19 Patients, Uses 3D Printed Adapter

In preparation for potential patient surge and shortage of critical mechanical ventilators for hospitalized COVID-19 patients, a Northwell Health physician, a respiratory therapist, and a 3D printing bioengineer have successfully designed the protocol to turn the more common bi-level positive airway pressure (BiPAP) machine into a functional invasive mechanical ventilator, through a 3D printed adaptor they also designed to aid in the conversion.

BiPAP is one type of PAP, or positive airway pressure, non-invasive machine that is commonly used to maintain a consistent breathing pattern at night or during symptom flare-ups in people with sleep apnea, congestive heart failure or chronic obstructive pulmonary disease (COPD), a chronic inflammatory lung disease.

As the health systems nationwide brace themselves for a potential increase in COVID-19 patients and New York Governor Andrew Cuomo calls for an increased supply of ventilators for hospitals statewide, a team led by Hugh Cassiere, MD, medical director for respiratory therapy services at North Shore University Hospital (NSUH) and Stanley John, NSUH’s director of respiratory therapy, developed a method to convert the non-invasive Philips Respironics V60 BiPAP machine into a pressure-controlled ventilator for both patients with and without COVID-19 induced lung disease.

“Our hospitals are at the US epicenter of the coronavirus epidemic, and some of our COVID-19 patients require intensive care unit therapy and mechanical ventilators within minutes of being hospitalized,” said Dr. Cassiere. One sleepless night, Dr. Cassiere thought of the fleet of unused BiPAP machines in the hospitals. “I knew we could develop a way to repurpose and convert these machines to save hundreds of lives.”

Currently, Northwell Health has an adequate supply of ventilators for its patients, and the health system is continually trying to obtain more ventilators to prepare for a likely surge. And while there are plans in place to handle a surge in patient volume, Northwell Health has a good supply of BiPAP machines across its 23 hospitals, and if faced with a surge when ventilator numbers do get low, it would be helpful to use these machines.

The key component to converting the BiPAP machine is a small, plastic T-piece adapter. Because of COVID-19 related supply change shortages, Dr. Cassiere and Stanley John collaborated with Northwell Health’s 3D Design and Innovation department, and together they designed and 3D printed a T-piece in a matter of days.

“We were able to imitate the design of the T-piece adapter and print the plastic-resin piece with our 3D printers,” said Todd Goldstein, Ph.D., director of 3D Design and Innovation at Northwell Health. “If the need arises, we would be able to print 150 adaptors in 24-hours.”

In an effort to help other hospital systems across the nation, Northwell Health will share the new protocols to convert the BiPAP machine as well as share the T-adapter 3D print design online.

Drs. Cassiere, Goldstein, and Stanley John successfully tested the conversion of the BiPAP machine using the standard, non-3D printed adaptor for both COVID-19 and non-COVID-19 patients. They have also tested the 3D printed T-adaptor and have ramped up production to adopt the 3D printed adaptor clinically in the coming days.

In addition to the T-piece adaptor, modifications to the BiPAP machine include the addition of two high-efficiency particulate air (HEPA) filters at both ends of the oxygen hose to alleviate fears of spreading the virus. They are also recommending using a blind reservoir connected to the last HEPA filter in the circuit.

Last week, Northwell Health, with collaborators at the University of South Florida (USF) and Formlabs, a leading 3D printing company, announced they produced and tested a 3D printed nasal swab to address emergency shortages that hospitals and health care teams may face as testing for COVID-19 increases.

 

enlightenVue Reports Single-Use Micro Endoscope Receives FDA 510(k) Clearance

enlightenVue creators of the surgiVue™ single-use platform of micro endoscopes announced today that their product has received 510(k) marketing clearance from the Federal Drug Administration (FDA).

According to the FDA: “The use of the enlightenVue Microendoscopy System is intended for the visualization of body cavities, hollow organs, and canals. It is also designed to be introduced through natural body orifices cavities or surgical incisions through introducers, trocars, needles, sheaths, or other devices with lumens having inside diameters larger than the outer diameter of the endoscope.”

Receiving this broad and general indication from the FDA gives enlightenVue the ability to market the unique surgiVue endoscope for multiple clinical and surgical procedures. EnlightenVue will immediately pursue several clinical trials in numerous medical and surgical specialties.

“This is the only two millimeter, single-use microendoscope on the market with two working channels,” said Giacomo Basadonna, Chief Executive Officer. “The surgiVue endoscope will protect patients from the risk of hospital-acquired infections that can be contracted from reusable endoscopes, as indicated by several FDA guidance documents. Additionally, the presence of two working channels allows health care providers to perform interventional procedures (rather than simple diagnostic ones) in a minimally invasive setting.”

“We are proud to have enlightenVue as an Alira Health Ventures portfolio company and are impressed with the speed and efficiency with which they achieved FDA clearance,” said Gabriele Brambilla, Chief Executive Officer of Alira Health and head of the firm’s investment arm, Alira Health Ventures. “It has only taken two and a half years from the initial sketch to 510(k) clearance, and this incredible technology is now poised to disrupt the market and offer a new level of safety and protection to patients.”

EnlightenVue’s microendoscope is single-use and does not require cleaning and/or re-sterilization, eliminating the risk of patient-to-patient transmission of microorganisms caused by difficult to disinfect and sterilize reusable endoscopes. This is of importance during the current viral pandemic where direct contagion must be avoided. In addition, the single-use surgiVue endoscope provides financial advantages to the healthcare system by eliminating the sterilization, repair and personnel costs associated with reusable endoscopes, reducing downtime and inventory logistics. The novel micro-endoscope allows for a combination of diagnostic and interventional procedures, simplifies the patient’s overall experience from diagnosis to treatment, and gives the provider a wide range of clinical options.

Roy Tanaka Joins S4 Medical’s Board of Directors

Roy Tanaka brings years of experience to S4. Tanaka joined Biosense Webster, a Johnson & Johnson company, in 1997 as U.S. president, and became its worldwide president in 2004 until his retirement in 2008.

A seasoned executive in the electrophysiology industry, Roy Tanaka brings years of experience to S4. Tanaka joined Biosense Webster, a Johnson & Johnson company, in 1997 as U.S. president, and became its worldwide president in 2004 until his retirement in 2008.  During his tenure, the company experienced tremendous growth to a market leadership position. Since then, he has served on the boards of TomoTherapy, Volcano, Coherex Medical, Epix Therapeutics, Thermedical, EP Dynamics, VytronUS, and Adventus Ventures. “I have known (S4 cofounder) Emile Daoud for many years, and I respect his extensive clinical experience and contributions to the world of electrophysiology,” Tanaka says. “I’m looking forward to being a part of the team that moves S4’s technology into the market, making a valuable difference in AF ablation.”

Dr. Emile Daoud, a coinventor, cofounder, and chief medical officer, says Tanaka’s leadership and knowledge in the field of electrophysiology brings a valuable perspective to the company. “Roy’s impact on the world of electrophysiology is enormous. His leadership introduced great advances in the technologies we use on a daily basis. We are building S4 for the next phase of development,” says Daoud, “and are grateful to add to our roster of talented directors who believe that this innovative technology will further our cause to bring safety and efficiency to ablation procedures.”

In the last year alone, S4 achieved several exciting milestones towards bringing the esolution device to market, including a successful first-in-human study, an issued patent, and a new round of funding. “S4 is on a fast pace to success and we are excited to have Roy Tanaka on the team. His knowledge, executive experience, industry contacts, and numerous successful product launches makes him the perfect addition to the S4 team,” says co-founder and CEO William Fuller.

Note: S4 Medical focuses on protecting the esophagus from damage during catheter ablation procedures. S4 Medical has developed a novel catheter called the “esolution” that utilizes a proprietary approach to deviate the esophagus.

GEP Introduces a Free Portal & Service to Connect Health Care Providers: Beginning with Hospitals in New York, New Jersey & Connecticut with PPE Suppliers

GEP, a leading provider of procurement and supply chain strategy, software and managed services to Fortune 500 companies, introduced a free portal — www.gep.com/covid19help/ — and service to connect health care providers — beginning with hospitals in the New York, New Jersey and Connecticut — with personal protective equipment (PPE) suppliers.

This service combines an online portal with the company’s procurement and supply chain specialists, for:

  1. Suppliers – with PPE equipment (N-95 masks, surgical masks, ventilators, isolation gowns, etc.) to be connected with the health care providers in need.
  2. Manufacturers/small businesses – to be connected with subject-matter experts for help in distributing excess capacity, repurposing equipment, or packaging.
  3. Health care providers – to provide details of their required PPE products to be connected with suppliers in GEP’s database.

GEP has proactively provided details of suppliers with PPE equipment to tri-state’s major hospital networks since mid-March. It is launching this portal to scale its effort to identify and connect the PPE suppliers with the health care providers.

1...898899900...923Page 899 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330